Inloggen
E-mail
Wachtwoord
Paswoord weergeven
Bewaren
Bent u uw wachtwoord vergeten?
Gratis lid worden
Registreer
Registreer
Instellingen
Instellingen
Dynamische koersen 
OFFON

ULTRAGENYX PHARMACEUTICAL INC.

(RARE)
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Nieuws in andere talen op ULTRAGENYX PHARMACEUTICAL INC.
11/01Ultragenyx reports preliminary 2021 revenue and 2022 revenue guidance for crysvita in u..
11/01Ultragenyx reports preliminary 2021 revenue and 2022 revenue guidance for crysvita in u..
10/01Regeneron and ultragenyx collaborate to commercialize evkeeza (evinacumab) outside the ..
10/01ULTRAGENYX PHARMACEUTICAL : REPORTS PRELIMINARY 2021 REVENUE AND 2022 REVENUE GUIDANCE FOR..
10/01ULTRAGENYX PHARMACEUTICAL INC. : Results of Operations and Financial Condition, Regulation..
10/01Ultragenyx Pharmaceutical Inc. Provides Earnings Guidance for the Year 2022
10/01Ultragenyx Reports Preliminary 2021 Revenue and 2022 Revenue Guidance for Crysvitaģ in ..
07/01Regeneron Pharmaceuticals, Ultragenyx Pharmaceutical Strike Commercialization Deal for ..
07/01Regeneron, Ultragenyx Ink International Deal on Cholesterol Drug Evkeeza
07/01ULTRAGENYX PHARMACEUTICAL INC. : Other Events, Financial Statements and Exhibits (form 8-K..
07/01ULTRAGENYX PHARMACEUTICAL : Evkeeza is a first-in-class medicine approved by the U.S. Food..
06/01Ultragenyx to Present at H.C. Wainwright BioConnect Healthcare Conference
05/01Ultragenyx, GeneTx Report Early Signs of Clinical Activity in Angelman Syndrome Trial
05/01Spruce Biosciences Names Javier Szwarcberg as CEO
05/01GeneTx and Ultragenyx Provide Preliminary Update on Phase 1/2 Clinical Study of GTX-102..
05/01GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. Provides Preliminary Upda..
03/01Ultragenyx to Present at 40th Annual JP Morgan Healthcare Conference
2021Genetx and ultragenyx announce presentations at upcoming 2021 fast global summit & gala
2021GeneTx and Ultragenyx†Announce Presentations at Upcoming†2021 FAST Global Summit & Gala
2021Ultragenyx Commences Dosing in Phase 1/2 Study of UX053 in Glycogen Storage Disease Typ..
2021Ultragenyx Announces First Patient Dosed in Phase 1/2 Clinical Study of UX053, an mRNA ..
2021Ultragenyx Pharmaceutical Inc. Announces First Patient Dosed in Phase 1/2 Clinical Stud..
2021Ultragenyx to Present at Evercore 4th Annual HealthconX Conference
2021Ultragenyx to Present at Evercore 4th Annual HealthconX Conference
2021Ultragenyx Announces Additional Positive Multi-Year Durability Data from Phase 1/2 AAV ..
2021Ultragenyx Pharmaceutical Inc. Announces New Long-Term Durability Data from Phase 1/2 S..
2021ULTRAGENYX PHARMACEUTICAL INC. Management's Discussion and Analysis of Financial Condi..
2021Ultragenyx Reports Third Quarter 2021 Financial Results and Corporate Update - Form 8-K
2021ULTRAGENYX : Q3 Earnings Snapshot
2021Earnings Flash (RARE) ULTRAGENYX PHARMACEUTICAL Reports Q3 Revenue $81.6M
2021Ultragenyx Pharmaceutical Inc. Reports Earnings Results for the Third Quarter and Nine ..
2021Ultragenyx Reports Third Quarter 2021 Financial Results and Corporate Update
2021EARNINGS REACTION HISTORY : Ultragenyx Pharmaceutical Inc, 100.0% Follow-Through Indicator..
2021Ultragenyx to Host Conference Call for Third Quarter 2021 Financial Results and Corpora..
2021ULTRAGENYX PHARMACEUTICAL : to Present at Jefferies Gene Therapy/Editing Summit
2021ULTRAGENYX PHARMACEUTICAL : Commences Trial Evaluating UX701 Gene Therapy for the Treatmen..
2021ULTRAGENYX PHARMACEUTICAL : Initiates Cyprus2+, a Pivotal Clinical Trial Evaluating UX701 ..
2021Ultragenyx Pharmaceutical Inc. Initiates Cyprus2+, A Pivotal Clinical Trial Evaluating ..
2021ULTRAGENYX PHARMACEUTICAL : GeneTx Report Dosing of First Pediatric Patient in Angelman Sy..
2021ULTRAGENYX PHARMACEUTICAL : GeneTx and Ultragenyx Announce First Patient Dosed in Canada i..
2021ULTRAGENYX PHARMACEUTICAL INC. : Other Events, Financial Statements and Exhibits (form 8-K..
2021ULTRAGENYX PHARMACEUTICAL : GeneTx and Ultragenyx Announce First Patient Dosed in Canada i..
2021Genetx Biotherapeutics LlLC and Ultragenyx Pharmaceutical Inc. Announce First Patient D..
2021ULTRAGENYX PHARMACEUTICAL : Reports inducement grant under nasdaq listing rule 5635(4)
2021ULTRAGENYX PHARMACEUTICAL : Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2021Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2021Mereo BioPharma and Ultragenyx Present Data from the Phase 2b ASTEROID Study of UX143 i..
2021ULTRAGENYX PHARMACEUTICAL : Mereo BioPharma and Ultragenyx Present Data from the Phase 2b ..
2021Mereo BioPharma Group plc and Ultragenyx Pharmaceutical Inc. Present Data from the Phas..
2021ULTRAGENYX PHARMACEUTICAL : Announces Crysvitaģ (burosumab) and UX143 (setrusumab) Data Pr..
2021Health Care Stocks Partially Recover From Earlier Slide
2021Health Care Stocks Retreating to Begin New Week
2021ULTRAGENYX PHARMACEUTICAL : GeneTx and Ultragenyx Announce FDA has Removed Clinical Hold o..
2021ULTRAGENYX PHARMACEUTICAL : GeneTx Say FDA Lifts Clinical Hold on Phase 1/2 Clinical Study..
2021ULTRAGENYX PHARMACEUTICAL INC. : Other Events, Financial Statements and Exhibits (form 8-K..
2021ULTRAGENYX PHARMACEUTICAL : GeneTx and Ultragenyx Announce FDA has Removed Clinical Hold o..
2021GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. Announce FDA has Removed ..
2021ULTRAGENYX, GENETX : FDA Removes Hold Study of GTX-102 in Angelman Syndrome
2021MEDIA ADVISORY : Ultragenyx Announces Mepseviiģ (vestronidase alfa) Receives Reimbursement..
2021Ultragenyx Pharmaceutical Inc. Announces Mepseviiģ (Vestronidase Alfa) Receives Reimbur..
2021Ultragenyx to Present at Morgan Stanley Healthcare Conference
2021ULTRAGENYX PHARMACEUTICAL : Says Crysvita Wins Canada Approval for Second Indication for E..
2021NOTE AUX MÉDIAS : Ultragenyx Canada annonce l'approbation par Santé Canada d'une deuxième ..
2021MEDIA ADVISORY : Ultragenyx Canada Announces Health Canada Approval of a Second Indication..
2021Ultragenyx Canada Announces Health Canada Approval of Second Indication for Crysvitaô (..
2021ULTRAGENYX PHARMACEUTICAL : to Participate in Panel at Citi's 16th Annual BioPharma Health..
2021ULTRAGENYX PHARMACEUTICAL : to Participate in Panel at Citi's 16th Annual BioPharma Health..
2021ULTRAGENYX PHARMACEUTICAL : Wins Brazilian Approval of Dojolvi for Treatment of Long-Chain..
2021Ultragenyx Announces Approval of Dojolviģ (triheptanoin) in Brazil for the Treatment of..
2021Ultragenyx Pharmaceutical Inc Announces Approval of Dojolviģ (triheptanoin) in Brazil f..
2021ULTRAGENYX PHARMACEUTICAL : Reports Inducement Grant Under Nasdaq Listing Rule 5635(4)
2021ULTRAGENYX PHARMACEUTICAL : Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2021HOY EN WALL STREET : ŅSigue en marcha la recuperación económica?
2021TODAY ON WALL STREET : Is the economic recovery still on track?
2021ULTRAGENYX PHARMACEUTICAL : to Participate in Gene Therapy Panel at Wedbush PacGrow Health..
1  2  3  4  5  6  7  8  9Volgende
Volgende evenement op ULTRAGENYX PHARMACEUTICAL INC.
22/02/22